Cost-revenue analysis of using a haemoadsorbent membrane in patients undergoing coronary artery bypass grafting with cardiopulmonary bypass and ticagrelor
In the French financial context, the use of the Cytosorb® in coronary artery bypass graft surgery with ticagrelor leads to additional costs, despite a slight revenue increase and the potential benefit of a shorter stay in the intensive care unit.
Authors
- Mickaël Vourc’h (ORCID: https://orcid.org/0000-0002-1576-7728)
- Nicolas Mauduit (ORCID: https://orcid.org/0009-0005-8433-2815)
- Yves Daniel Compaoré (ORCID: https://orcid.org/0000-0001-8848-2187)
- Fabien Nativel (ORCID: https://orcid.org/0000-0001-5917-1996)
- Mark L. Ryan (ORCID: https://orcid.org/0000-0001-6553-5442)
- Julien Cadiet
- Charles‐Henri David (ORCID: https://orcid.org/0000-0002-7625-5056)
- Valéry-Pierre Riche
- Johann Clouet
- Benjamin Mathat
Institutions
- Inserm (FR)
- Centre Hospitalier Universitaire de Nantes (FR)
- Centre d'Investigation Clinique de Nantes (FR)
- Nantes Université (FR)
Publication Details
- Journal
- Archives of cardiovascular diseases
- Published
- 2025-09-02
- DOI
- https://doi.org/10.1016/j.acvd.2025.07.011
- Primary Topic
- Mechanical Circulatory Support Devices
- Type
- article
- Field-Weighted Citation Impact
- 0.00